Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

velpatasvir

- PMLiVE

NICE backs Gilead’s Sovaldi in hepatitis C

But health watchdog denies earlier use of Janssen’s Zytiga

- PMLiVE

AbbVie begins ‘first-of-its-kind’ hep C charity pilot

Will work with Addaction Cornwall and The Hepatitis C Trust

- PMLiVE

Two blood cancer drugs among CHMP recommendations

Five new drugs, including Janssen’s Imbruvica and Gilead’s Zydelig, backed for use in Europe

- PMLiVE

FDA approves Gilead drug in three blood cancers

Zydelig recommended for use in chronic lymphocytic leukaemia and two forms of lymphoma

- PMLiVE

Olysio leads charge at J&J but competition is on the way

CEO Gorsky warns that Gilead’s Sovaldi will impact sales of hepatitis C drug

- PMLiVE

US senators seeks answers on Sovaldi pricing

Gilead asked to justify pricing of hepatitis drug

The seven letter debate that is Sovaldi

Reimbursement of high cost hepatitis C drugs raise difficult issues

- PMLiVE

Janssen-backed report calls on governments to tackle hepatitis C

Report finds that national policies do not adequately address disease

- PMLiVE

Boehringer pulls faldaprevir and exits hepatitis C market

Unable to challenge all-oral options from Gilead and others

Gilead Sciences

Sovaldi stumbles as NICE assesses hep C drug’s price

Gilead must provide much more cost-effectiveness information

AbbVie closes in on US approval of all-oral hepatitis C regimen

FDA grants priority review to company’s protease inhibitor ABT-450 regimen

- PMLiVE

Merck agrees $3.85bn deal for hepatitis specialist Idenix

Opens up direct challenge to Gilead

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links